TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02958722

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: diagnostic hysteroscopy
Description: Endoscopic procedure to visualize uterine cavity

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: diagnostic hysteroscopy
Description: Endoscopic procedure to visualize uterine cavity
Study: NCT04126395

Intervention type: DIAGNOSTIC_TEST
Intervention: Social Responsiveness Scale 2 (SRS-2)
Description: The SRS-2 is a parent questionnaire designed to identify social impairments associated with ASD in children 4 trough 18 years of age. We will used Dutch norms.
Study: NCT02765256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: ciprofloxacin 750 mg orally twice daily (Day 4-14)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ciprofloxacin
Description: ciprofloxacin 750 mg orally twice daily (Day 4-14)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol 3350
Description: 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Polyethylene Glycol 3350
Description: 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promethazine
Description: PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Promethazine
Description: PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluconazole placebo
Description: Once daily
Study: NCT04800640

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Electroanalgesia
Description: The sample will consist of 66 individuals, of both men and women, where they will be randomly included in two groups: Intervention group composed of 33 patients who will effectively receive the treatment through electroanalgesia via TENS;
Study: NCT02498002

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Monitoring (Actiheart)
Description: Monitor physical activity using an Actiheart monitor during the required periods.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physical Activity Monitoring (Actiheart)
Description: Monitor physical activity using an Actiheart monitor during the required periods.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physical Activity Monitoring (Actiheart)
Description: Monitor physical activity using an Actiheart monitor during the required periods.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Energy Intake Monitoring
Description: Monitor energy intake by weighing and recording all foods/drinks consumed during the required periods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Intake Monitoring
Description: Monitor energy intake by weighing and recording all foods/drinks consumed during the required periods.
Study: NCT04126395

Intervention type: OTHER
Intervention: Retrospective Video Analysis
Description: Retrospective video analysis will be used to explore motor development in children with DCD, DCD+ASD and controls.

Intervention type: OTHER
Intervention: Retrospective Video Analysis
Description: Retrospective video analysis will be used to explore motor development in children with DCD, DCD+ASD and controls.

Intervention type: OTHER
Intervention: Retrospective Video Analysis
Description: Retrospective video analysis will be used to explore motor development in children with DCD, DCD+ASD and controls.
Study: NCT02498002

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Intake Monitoring
Description: Monitor energy intake by weighing and recording all foods/drinks consumed during the required periods.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Body Weight Monitoring
Description: Monitor body weight during monitoring phase to ensure stability despite other monitoring activities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body Weight Monitoring
Description: Monitor body weight during monitoring phase to ensure stability despite other monitoring activities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body Weight Monitoring
Description: Monitor body weight during monitoring phase to ensure stability despite other monitoring activities.
Study: NCT02958722

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: physiological solution
Study: NCT02498002

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Cannulation
Description: Fitting of an intravenous cannula to a vein on the forearm for blood sampling during laboratory protocols.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous Cannulation
Description: Fitting of an intravenous cannula to a vein on the forearm for blood sampling during laboratory protocols.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous Cannulation
Description: Fitting of an intravenous cannula to a vein on the forearm for blood sampling during laboratory protocols.
Study: NCT02958722

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carbon dioxide
Study: NCT02498002

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adipose Tissue Biopsy
Description: This is an optional feature which if included involves the removal of a 0.5 gram sample of adipose tissue from just below the skin using a needle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adipose Tissue Biopsy
Description: This is an optional feature which if included involves the removal of a 0.5 gram sample of adipose tissue from just below the skin using a needle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adipose Tissue Biopsy
Description: This is an optional feature which if included involves the removal of a 0.5 gram sample of adipose tissue from just below the skin using a needle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: The anaesthetic that will be used to numb the site of the adipose tissue biopsy in the event it is included.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: The anaesthetic that will be used to numb the site of the adipose tissue biopsy in the event it is included.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: The anaesthetic that will be used to numb the site of the adipose tissue biopsy in the event it is included.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post-Prandial Meal Tests
Description: Consume two successive meals with regular blood samples throughout the ensuing hours (2-3 hours each).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-Prandial Meal Tests
Description: Consume two successive meals with regular blood samples throughout the ensuing hours (2-3 hours each).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-Prandial Meal Tests
Description: Consume two successive meals with regular blood samples throughout the ensuing hours (2-3 hours each).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: DEXA Scan
Description: Undergo a dual energy x-ray absorptiometry scan to examine body composition.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: DEXA Scan
Description: Undergo a dual energy x-ray absorptiometry scan to examine body composition.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: DEXA Scan
Description: Undergo a dual energy x-ray absorptiometry scan to examine body composition.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Actiheart Calibration
Description: Submaximal treadmill test to calibrate monitoring equipment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actiheart Calibration
Description: Submaximal treadmill test to calibrate monitoring equipment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actiheart Calibration
Description: Submaximal treadmill test to calibrate monitoring equipment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Daily Calorie Restriction
Description: Reduce energy intake by 25% on a daily basis.
Study: NCT03249285

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peri
Description: Perindopril 4 mg /day, orally with titration to 8 mg/day after 1 month if BP (Blood pressure) is not controlled
Study: NCT00680654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521)
Description: The investigational drug will be given twice per subject, as single dose administration of BAY 63-2521 (0.5 mg and 1.0 mg) during the hemodynamic investigation.
Study: NCT05863676

Intervention type: PROCEDURE
Intervention: Oophorectomy
Description: Ovary will be removed for fertility preservation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Infectious Disease Testing
Description: Infectious Disease Testing will be done on participants.
Study: NCT00576550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urea
Description: Urea cream applied twice daily up to six months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: betamethasone valerate
Description: Application once daily for two weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: betamethasone valerate
Description: Application twice daily for two weeks
Study: NCT01352026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT03956927

Intervention type: OTHER
Intervention: S-TPE
Description: S-TPE stimulation session with groups of 8 patients. The simulation is performed by a single patient, the others are observers in a neighbouring room where the scene is projected.

Intervention type: OTHER
Intervention: Questionnaires
Description: Pre- and post-simulation administration of self-efficacy and anxiety questionnaires (IASTA Y1 and Y2)
Study: NCT02690792

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NAFLD/NASH - Placebo
Description: Placebo capsules, 2 capsules by mouth each morning and 2 capsules by mouth each evening for 4 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NAFLD/NASH - Vitamin E
Description: Vitamin E 200 IU capsule, 2 capsules by mouth each morning and 2 capsules by mouth each evening for 4 months.
Study: NCT02378584

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: embryo transfer
Description: healthy blastocyst transfer in natural and hormonal cycle

Intervention type: OTHER
Group type: OTHER
Intervention: embryo transfer
Description: healthy blastocyst transfer in natural and hormonal cycle
Study: NCT02498002

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting with Weight Loss
Description: Alternate between 24 hour cycles of fasting and feeding with 150% of normal intake when feeding.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting without Weight Loss
Description: Alternate between 24 hour cycles of fasting and feeding with 200% of normal intake when feeding.
Study: NCT04081909

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl，Remifentanil
Description: Patients in OBA ,anesthesia induction will receive fentanyl 2ug/kg ,propofol 1% 2-3mg/kg, rocuronium 0.6-1mg/kg. Anesthesia maintenance with 1.5-2% sevoflurane, propofol 1% 3-6mg/kg/hr , remifentanil of 0.1- 0.2ug/ kg/ min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine,Dexmedetomidine
Description: Patients in OFA,anesthesia induction will receive ketamine 1 mg/kg ,propofol 1% 2-3mg/kg, rocuronium 0.6-1mg/kg. Anesthesia maintenance with 1.5-2% sevoflurane, propofol 1% 3-6mg/kg/hr , dexmedetomidine of 0.4-0.8ug/ kg/ hr.
Study: NCT01549405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: İntercostal nerve block
Description: Nerve block group was administered two levels intercostal block (11 and 12th ribs) with 0.5% bupivacaine with epinephrine before surgery.
Study: NCT01261897

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor-Canal-Blockade with Ropivacaine
Description: US-guided Adductor-Canal-Blockade with ropivacaine 7,5 mg/ml

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Adductor-Canal-blockade with saline
Description: US-guided Adductor-Canal-blockade with saline
Study: NCT04132687

Intervention type: PROCEDURE
Group type: OTHER
Intervention: autologous blood patch therapy
Description: use autologous blood as blood patch therapy in persistent air leak
Study: NCT02321059

Intervention type: DEVICE
Intervention: Measurement of abdominal wall strength
Description: Test-retest examination of the reliability of the Goodstrength trunk dynamometer

Intervention type: DEVICE
Intervention: Measurement of abdominal wall strength
Description: Test-retest examination of the reliability of the Goodstrength trunk dynamometer
Study: NCT01954862

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Air Insufflation method.
Description: Air Insufflation method.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Description: CO2 insufflation.
Study: NCT03249285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peri
Description: Perindopril 4 mg /day, orally with titration to 8 mg/day after 1 month if BP (Blood pressure) is not controlled

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCTZ
Description: Hydrochlorothiazide 12, 5 mg day, orally with titration to 25 mg/day after 1 month if BP is not controlled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCTZ
Description: Hydrochlorothiazide 12, 5 mg day, orally with titration to 25 mg/day after 1 month if BP is not controlled
Study: NCT03981133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: offer a pacifier
Description: offer a pacifier to normal newborn infants the first days of life

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: no pacifier
Description: not to offer a pacifier at 15 days of life
Study: NCT03740386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentolamine Mesylate 0.235 MG/ML [OraVerse]
Description: compare effect of phentolamine mesylate in three arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentolamine Mesylate 0.235 MG/ML [OraVerse]
Description: compare effect of phentolamine mesylate in three arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentolamine Mesylate 0.235 MG/ML [OraVerse]
Description: compare effect of phentolamine mesylate in three arms
Study: NCT02721147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intimacy Enhancing Intervention
Description: Participants attend 4 intimacy enhancement intervention sessions over 75 minutes every other week for 4 weeks. The intimacy enhancement intervention comprises 4 main sessions: understanding impact of breast cancer on sex and intimacy, communication about sex/intimacy, problem-solving and changing thoughts, and planning ahead and preparing for challenges. Participants are encouraged to participate in written and behavioral activities at home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Living Healthy Together
Description: Participants receive educational information and support about breast cancer every other week for 4 weeks. The educational information and support comprises topics about breast cancer, its treatments, sleep, energy, stress, stress management, nutrition, and diet. Participants are encouraged to read educational materials.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partner-Assisted Coping Skills Training
Description: Receive couple-based intimacy enhancement intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral, Psychological or Informational Intervention
Description: Receive educational information and support
Study: NCT03805022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: A treatment cycle consists of 3 weeks. Doxorubicin will be administered from day 1 to day 3 (60 or 75mg/m² day or 20 or 25 mg/m² per day), repeated every 3 weeks, up to 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide or dacarbazine
Description: A treatment cycle consists of 3 weeks. Treatment may continue up to 3 cycles. Ifosfamide will be administered from day 1 to day 3 (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices, repeated every 3 weeks, up to 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: A treatment cycle consists of 3 weeks. Doxorubicin will be administered from day 1 to day 3 (60 or 75mg/m² day or 20 or 25 mg/m² per day), repeated every 3 weeks, up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide or dacarbazine
Description: A treatment cycle consists of 3 weeks. Ifosfamide will be administered from day 1 to day 3 (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices, repeated every 3 weeks, up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: At the discretion of the investigator
Description: Drug at the discretion of the investigator.
Study: NCT02712944

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: Testosterone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo
Study: NCT01289847

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gammaplex
Description: GAMMAPLEX 5g/100 mL, dose is 300-800 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with GAMMAPLEX will be 12 months with a 3 month follow-up.
Study: NCT02051036

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Moxibustion
Description: In the moxibustion treatment group, 5 moxibustion points (bilateral SP6, LV3 and unilateral CV4) will be heated with indirect moxibustion (KangHwa, Korea).~The moxa pillars will be removed when the patient feel hotness and require to remove them.~The moxibustion will be conducted repeatedly unless patients feel the sense of heat up to seven times per session.
Study: NCT00579111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath
Description: 10 mg/day IV daily for 3 days on days -6 to D-4. Campath may be omitted from the conditioning regimen for patients with malignant diseases and matched related donor transplants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath
Description: 10 mg/day IV daily for 3 days on days -6 to D-4. Campath may be omitted from the conditioning regimen for patients with malignant diseases and matched related donor transplants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 3.2 mg/kg/day IV daily for 2 days, infused over 3 hours, on Day -5 and Day -4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 3.2 mg/kg/day IV daily for 2 days, infused over 3 hours, on Day -5 and Day -4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m2/day IV daily for 4 days on Day -5 to D -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m2/day IV daily for 4 days on Day -5 to D -2

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell infusion
Description: Peripheral blood stem cells when possible. Bone marrow cells will be used if peripheral blood cells are insufficient or unavailable.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell infusion
Description: Peripheral blood stem cells when possible. Bone marrow cells will be used if peripheral blood cells are insufficient or unavailable.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK-506
Description: FK-506 at a dose of 0.03 mg/kd/day will be administered via continuous infusion over 24 hours from 4pm on Day -2 until engraftment or when the patient is able to take PO, then 0.03 mg/kg PO every 12 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK-506
Description: FK-506 at a dose of 0.03 mg/kd/day will be administered via continuous infusion over 24 hours from 4pm on Day -2 until engraftment or when the patient is able to take PO, then 0.03 mg/kg PO every 12 hours.
Study: NCT03782428

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: 30 billions colony-forming unit (CFU) of a mixture of six viable strains including 107 mg of Lactobacillus acidophilus BCMC® 12130, Lactobacillus lactis BCMC® 12451, Lactobacillus casei subsp BCMC® 12313, Bifidobacterium longum BCMC® 02120, Bifidobacterium bifidum BCMC® 02290 and Bifidobacterium infantis BCMC® 02129

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo samples produced were identical to the probiotics in term of taste and texture without live microorganisms.
Study: NCT03943563

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Dixon sequences acquisition
Description: Dixon sequences acquisition
Study: NCT01216475

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femtosecond LASIK
Description: LASIK consists of two steps: the first step involves the formation of a corneal flap and the second one is when the excimer ablation is performed in the corneal stromal bed. Femtosecond lasers (FL) have been widely used in LASIK surgery to fashion the corneal flap. The laser will cut a lamellar followed by a vertical corneal incision. We are able to produce a vertical cut since the Femtosecond laser can deliver laser pulses of 1 micron diameter at a preselected depth in the cornea, which then expands to 2 to 3 microns with the formation of a cavitation bubble. These pulses create micro-photodisruption of the corneal tissue by the formation of an expanding bubble of carbon dioxide and water, which in turn cleaves the tissue and creates a plane of separation. The flap is then removed to expose the stroma and the refractive treatment is done by the excimer laser over the denuded stroma.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Small incision lenticule extraction (SMILE)
Description: Patient's eye will be centered and docked with the curved interface cone before application of suction fixation. First, the posterior surface of the refractive lenticule (spiral in), then the lenticule border is created. The anterior surface of the refractive lenticule (spiral out) is then formed which extended beyond the posterior lenticule diameter by 0.5mm to form the anterior flap and is followed by a rim cut. After the suction is released, a Siebel spatula is inserted under the flap near the hinge before the flap is seperated and reflected. The edge of the refractive lenticule is separated from the stromal bed with a sinsky hook and the posterior border of the lenticule gently separated with the Siebel spatula and removed through small incision.